Home » Topics » BioWorld Science

BioWorld Science
RSS

FDA grants fast track designation to L1-79 for use in autism spectrum disorder

May 15, 2018

Concentric reports topline phase Ib data for CA-008 in postsurgical pain

May 15, 2018

FDA approves Briviact oral formulations for the treatment of pediatric patients

May 15, 2018

Alkahest initiates two phase II trials of ALK-4290 in age-related macular degeneration

May 15, 2018

First patients enrolled in phase IIa trial of ORY-2001 in Alzheimer's disease

May 15, 2018

CS-1003 begins phase I trial in advanced solid tumors

May 14, 2018

Polaris collaborates with MD Anderson Cancer Center to utilize immunotherapy platform

May 14, 2018

Poseida Therapeutics presents clinical data on P-BCMA-101 for relapsed/refractory multiple myeloma

May 14, 2018

Beam Therapeutics launches with focus on creating precision genetic medicines through base editing

May 14, 2018

Human evaluation of CAR T cells targeting ROR1 underway

May 14, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 1, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
New evidence links autoimmunity to long COVID symptoms
BioWorld
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections
BioWorld
GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...